Latest Licensing News

Ceretas Limited posted a $1.63 million net loss for FY26 on $1.28 million revenue from government grants, advancing its clinical-stage Alzheimer’s ultrasound platform. The company completed an $8 million IPO in July to fund pivotal trials and device development.

AUCyber Limited reported a 28% revenue decline to $19.98 million in FY26 but cut its net loss by 87% to $4.78 million, driven by exiting low-margin contracts and cost discipline. CEO Joseph Demase now also serves as Chair, steering a strategic shift towards sovereign AI and private cloud solutions.

5G Networks grew revenue by 13% to $71.4 million in FY26, buoyed by enterprise and cloud services including its cyber security acquisition AUCyber. Despite positive underlying EBITDA, net losses widened due to acquisition-related costs as the company pursues integration and data centre growth.

Liontown Limited (ASX:LTR) has reported its maiden profit and strong cash flow in FY26, completing its transition to fully underground mining at Kathleen Valley and advancing expansion plans with a final investment decision due early FY27.

PT ANTAM (ASX:ATM) posted a 6% increase in net sales to Rp62.71 trillion in the first half of 2026, driven by steady gold, nickel, and bauxite sales. Profit after tax surged 34% to Rp6.91 trillion, supported by improved margins and foreign exchange gains.

Enprise Group reported a $2.2 million net loss for FY2026 amid rising revenue and cost pressures, prompting a strategic reset aimed at returning to profitability in FY2027.

Cambium Bio has secured FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development costs and timelines. Despite a AUD 4.1 million loss for FY2026, the company strengthened its funding position and manufacturing partnerships ahead of patient dosing targeted for late 2026.

First Graphene lifted revenue by 15% to $537,594 for FY26 while narrowing its net loss slightly to $5.4 million. Key acquisitions and a landmark China cement distribution MOU set the stage for commercial expansion.

Paradigm Biopharmaceuticals has surpassed its Phase 3 enrolment target for Zilosul®, secured over A$21 million in capital, and pivots towards clinical evidence generation with major data readouts expected.

Berkeley Energia reported a $8.7 million net loss for FY2026 while pushing forward with its Salamanca uranium project and maiden critical minerals resource at Conchas. The company continues a $1.25 billion ICSID arbitration claim against Spain over permitting delays.

Spacetalk Ltd reported a 17% revenue decline in FY26 amid a strategic reset, but mobile revenue grew 16% as the company pivots to a software-led family safety platform supported by new telco partnerships.

Bisalloy Steel’s FY26 profit fell 16% as softer domestic demand and Indonesian import restrictions weighed, but the company secured a pioneering US submarine steel order and advanced its digital wear-monitoring technology.